Interestingly, the KRAS activation appeared in contrasting instances between the following two types of samples: in bulk tumors, the KRAS-down gene set was activated in the “early relapse” group, while in invasion front samples, the KRAS-up gene set was activated in the same group of patients, indicating a differential activation of KRAS between bulk tumor and invasion front regions within early CC. Here, KRAS is linked to neoplasm.